In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 840-844

  Haas, Wolfgang ^a   Pillar, Chris M ^b   Hesje, Christine K ^a   Sanfilippo, Christine M ^a   Morris, Timothy W ^a  

^a BAUSCH AND LOMB   (United States)

^b Eurofins Medinet Inc   (Germany)

Author keywords

Bactericidal activity; Fluoroquinolones; Time kill study

Indexed keywords

BENZALKONIUM CHLORIDE; BESIFLOXACIN; GATIFLOXACIN; MOXIFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM EXAMINATION; COMPARATIVE STUDY; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TEAR FILM;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; AZEPINES; BACTERIA; BENZALKONIUM COMPOUNDS; DRUG INTERACTIONS; FLUOROQUINOLONES; MICROBIAL VIABILITY; QUINOLINES; TIME FACTORS;

EID: 79952790007     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq531     Document Type: Article

References (12)

1. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999; 12: 147-79.
2. Callegan MC, Novosad BD, Ramadan RT et al. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Adv Ther 2009; 26: 447-54.
3. Kowalski RP, Kowalski BR, Romanowski EG et al. The in vitro impact of moxifloxacin and gatifloxacin concentration (0.5% vs 0.3%) and the addition of benzalkonium chloride on antibacterial efficacy. Am J Ophthalmol 2006; 142: 730-5.
4. Haas W, Pillar CM, Hesje CK et al. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 2010; 65: 1441-7.
5. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Eighth Edition: Approved Standard M7-A8. CLSI, Wayne, PA, USA, 2009.
6. Clinical and Laboratory Standards Institute. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. CLSI, Wayne, PA, USA, 1999.
7. Friedlaender MH, Breshears D, Amoozgar B et al. The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther 2006; 23: 835-41.
8. Hesje CK, Borsos SD, Blondeau JM. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains. J Ocul Pharmacol Ther 2009; 25: 329-33.
9. Drlica K, Malik M, Kerns RJ et al. Quinolone-mediated bacterial death. Antimicrob Agents Chemother 2008; 52: 385-92.
10. Proksch JW, Granvil CP, Mermet-Siou R et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther 2009; 25: 335-44.
11. Karpecki P, DePaolis M, Hunter JA et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther 2009; 31: 514-26.
12. Tepedino ME, Heller WH, Usner DW et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin 2009; 25: 1159-69.